CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

First posted Jun 12, 2003

Single Dose Pharmacokinetic (PK) Study

12 participants · First posted Apr 12, 2017

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

141 participants · First posted Mar 20, 2019

OAV401

OXC071

WSK-V401

Ovid Therapeutics Reports First-in-Human Safety Data for Novel KCC2 Direct Activator OV350

Ovid Therapeutics Secures $175M PIPE Financing to Advance CNS Drug Pipeline Through 2028

Ovid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million